We are live on
!
Find out more
ACM
Ashford Capital Management Portfolio holdings
AUM
$809M
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+14.91%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.15%
5 Year Est. Return
+109.93%
10 Year Est. Return
+1,281.06%
AUM
$746M
AUM Growth
+$67.1M
(+9.9%)
Cap. Flow
-$5.67M
Cap. Flow
% of AUM
-0.76%
Top 10 Holdings %
Top 10 Hldgs %
36.16%
Holding
95
New
4
Increased
32
Reduced
37
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Skyward Specialty Insurance
SKWD
|
+$12.3M |
| 2 |
Cellebrite
CLBT
|
+$11.6M |
| 3 |
Progyny
PGNY
|
+$9.89M |
| 4 |
CYBR
CyberArk
CYBR
|
+$9.73M |
| 5 |
ODDITY Tech
ODD
|
+$8.93M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Harmony Biosciences
HRMY
|
+$14.2M |
| 2 |
Vicor
VICR
|
+$13.7M |
| 3 |
CSGS
CSG Systems International
CSGS
|
+$11.2M |
| 4 |
Copart
CPRT
|
+$6M |
| 5 |
Goosehead Insurance
GSHD
|
+$5.86M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.06% |
| 2 | Healthcare | 18.58% |
| 3 | Financials | 17.18% |
| 4 | Industrials | 12.27% |
| 5 | Communication Services | 5.06% |
Similar funds
BDWCC
IPW
BWS
SSG
BBI
RPAM
PS
UAG
Ashford Capital Management's Q4 2023 Portfolio in Review
As of Q4 2023, Ashford Capital Management held 95 positions worth $746M, up 9.9% from $679M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Ashford Capital Management's Q4 2023 filing shows 4 new, 32 increased, 37 reduced and 2 closed positions. Its largest new stake was Cellebrite: 1,491,100 shares worth $12.9M. The largest sale was Harmony Biosciences, an estimated $14.2M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 24% a quarter earlier, followed by Healthcare and Financials.
- Ashford Capital Management's largest Q4 2023 buy was Cellebrite: 1,491,100 shares worth $12.9M.
- Ashford Capital Management added most to Skyward Specialty Insurance in Q4 2023, an estimated $12.3M increase.
- Ashford Capital Management's biggest Q4 2023 reduction was Vicor, cutting an estimated $13.7M.
- Ashford Capital Management fully exited Harmony Biosciences in Q4 2023, selling an estimated $14.2M.
- Ashford Capital Management's ten largest holdings make up 36% of its $746M portfolio in Q4 2023.
- Ashford Capital Management opened 4 new positions and closed 2 in Q4 2023.
- Ashford Capital Management's portfolio value rose 9.9% quarter-over-quarter to $746M.
Based on Ashford Capital Management's 13F filing for Q4 2023, filed 15 Feb 2024.